Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Pelthos Therapeutics Inc. (PTHS)

Pelthos Q2 net product revenue rises 45% to $15.4 million; Q1 2026 results to be restated

Mixed Impact 5 of 5 earnings Written later

Pelthos reported second quarter 2026 net product revenue for Zelsuvmi of $15.4 million, up 45% from the first quarter, and a net loss of $23.4 million, narrower than the restated $25.1 million loss for the first quarter. The company also said its previously issued first quarter 2026 financial statements should no longer be relied upon and should be restated, and its stockholders' equity was a deficit of $(1.5) million at June 30, 2026.

Key points

  • Q2 2026 net product revenue was $15.4 million, up from $10.7 million in Q1 2026, a 45% increase
  • Q2 2026 net loss was $(23.4) million versus a restated $(25.1) million in Q1 2026; Adjusted EBITDA was $(5.7) million versus $(8.0) million
  • Q1 2026 financial statements should no longer be relied upon, per a separate Item 4.02 filing referenced in this 8-K
  • Total stockholders' equity was $(1.5) million at June 30, 2026, compared with $38.9 million at December 31, 2025; cash was $24.2 million

The filing

CompanyPelthos Therapeutics Inc. (PTHS)
Form8-K, current report
Filed with the SECAug 13, 2026, 7:15 AM ET
Accession number0001919246-26-000112

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.